Is TG Therapeutics Inc. (TGTX) Good For Your Portfolio?

0
11

TG Therapeutics Inc. (NASDAQ:TGTX) saw an upside of 14.03% to close Tuesday at $14.47 after adding $1.78 on the day. The 5-day average trading volume is 4,367,360 shares of the company’s common stock. It has gained $14.67 in the past week and touched a new high 2 times within the past 5 days. An average of 9,391,521 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 5,937,522.

TGTX’s 1-month performance is 63.87% or $6.35 on its low of $6.88 reached on 12/28/22. The company’s shares have touched a 52-week low of $3.48 and high of $15.26, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, TGTX has achieved 22.32% or $2.64 and has reached a new high 5 times. However, the current price is down -5.18% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Insider Transactions

TGTX stock investors last saw insider trading activity on Jan 06.Charney Laurence N (Director) most recently sold 30,000 shares at $11.10 per share on Jan 04. This transaction cost the insider $333,000.

Valuation Metrics

TGTX stock has a beta of 1.96. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 402.87 while the price-to-book (PB) in the most recent quarter is 19.55.

TG Therapeutics Inc.’s quick ratio for the period ended September 29 was 5.00, with the current ratio over the same period at 5.00. As well, the company’s long term debt to equity for the quarter ending September 29 was 0.70, while the total debt to equity was 0.70.. In terms of profitability, the gross margin trailing 12 months is 90.60%. The firm’s gross profit as reported stood at $5.9 million against revenue of $6.69 million.

Earnings Surprise

For the quarterly period ending September 29 this year, TG Therapeutics Inc.’s cash and short-term investments amounted to $66.08 million against total debt of $82.36 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -139.08% to -$35.82 million, while revenue of -$40.51 million was -13.09% off the previous quarter. Analysts expected TGTX to announce -$0.34 per share in earnings in its latest quarter, but it posted -$0.26, representing a 23.50% surprise. EBITDA for the quarter stood at more than -$34.53 million. TGTX stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 117.41 million, with total debt at $82.36 million. Shareholders hold equity totaling $145.34 million.

Let’s look briefly at TG Therapeutics Inc. (TGTX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 72.91% to suggest the stock is trending Overbought, with historical volatility in this time period at 95.62%.

The stock’s 5-day moving average is $12.65, reflecting a +12.34% or $1.59 change from its current price. TGTX is currently trading +68.65% above its 20-day SMA, +113.74% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +180.43% and SMA200 by+37.94%.

Stochastic %K and %D was 74.96% and 67.31% and the average true range (ATR) pointed at 1.11. The RSI (14) points at 69.83%, while the 14-day stochastic is at 95.73% with the period’s ATR at 1.09. The stock’s 9-day MACD Oscillator is pointing at 0.27 and 0.91 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for TG Therapeutics Inc. (NASDAQ: TGTX), BofA Securities launched coverage with an Underperform rating. Analysts offering their rating for TGTX stock have a consensus rating for the stock as Overweight. Currently, 1 brokerage advisors rate TGTX as a “sell,”, while 0 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 0 rates the stock as overweight while 7 have offered a “buy” rating.

What is TGTX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $6.00 and a high of $40.00, with their median price target at $23.00. Looking at these predictions, the average price target given by analysts is for TG Therapeutics Inc. (TGTX) stock is $21.56.

LEAVE A REPLY

Please enter your comment!
Please enter your name here